Figure 1
From: Menin-MLL inhibitors as a new therapeutic target for middle ear cholesteatoma
The menin-MLL inhibitors inhibit the growth rate and the expression level of cyclin D1 (CCND1) of mouse-derived primary tympanic membrane epithelial cells (TMECs) in vitro. (a) Growth rate of the TMECs in CnT-PR media for 1, 3, and 5 days in the absence (PBS, circle, line) or presence of 0.5 µM (triangle, dashed line) or 1.0 µM (square, dotted line) menin-MLL inhibitors (BMF-219, VTP50469, MI-463, MI-2). The cells were used at passage 3. Data shown are mean ± SD (n = 3). ***, p < 0.001, **, p < 0.01, *, p < 0.05, ns, non-significant (one-way analysis of variance test, followed by Dunnett’s tests for normally distributed data). d0, Day 0, d1, Day 1, d3, Day 3, d5, Day 5. (b) Western blot analysis using antibodies against cyclin D1 (CCND1). The expression level of CCND1 in the TMECs was reduced after administration of the 0.5 µM or 1.0 µM menin-MLL inhibitors (BMF-219, VTP50469, MI-463, MI-2). β-actin was used as a loading control. The full blots are shown in Supplementary Fig. S1. Data shown are mean ± SD (n = 3). ****, p < 0.0001 (one-way analysis of variance test, followed by Dunnett’s tests for normally distributed data).
